G Venkata Avinash¹, Ratan Pal Yadav²*, Srilaxmi N¹3 and B Vijaya Lakshmi⁴

¹Post Graduate, Department of Pediatrics, NRI Medical College and Superspeciality Hospital, Chinakakani, Mangalagiri, Guntur, Andhra Pradesh, India
²MBBS, Department of Pediatrics, NRI Medical College and Superspeciality Hospital, Chinakakani, Mangalagiri, Guntur, Andhra Pradesh, India
³Senior Resident, Department of Pediatrics, NRI Medical College and Superspeciality Hospital, Chinakakani, Mangalagiri, Guntur, Andhra Pradesh, India
⁴Professor and HOD, Department of Pediatrics, NRI Medical College and Superspeciality Hospital, Chinakakani, Mangalagiri, Guntur, Andhra Pradesh, India

*Corresponding Author: Ratan Pal Yadav, MBBS, Department of Pediatrics, NRI Medical College and Superspeciality Hospital, Chinakakani, Mangalagiri, Guntur, Andhra Pradesh, India.

Received: February 21, 2023; Published: March 13, 2023

Abstract

SARS-CoV-2 is a novel coronavirus which continues to spread and remains a threat to human life across the globe. The paediatric Population infected with the virus are usually asymptomatic or exhibit mild symptoms. MIS-C is a new dangerous childhood disease that occurs 4- 6 weeks after SARS-CoV-2 infection. Worldwide it was first reported in April 2020 in UK. In India 1^st reported in KKCTH, Chennai. Most affected children have positive serology for SARS-CoV-2 with a negative PCR showing that MIS-C is related to immune dysregulation occurring after acute infection has passed. Children with MIS-C may manifest some combinations of fever, rash, conjunctivitis, GI symptoms, cardiac dysfunction. This can be related to systemic inflammatory response due to Covid 19, which can have clinical features similar to dengue fever. As dengue is endemic in our region, making diagnosis of MIS-C during dengue season is will be delayed because of sharing of clinical features in severe dengue cases. It can be fatal without early diagnosis and appropriate management in MIS-C.

Keywords: SARS-CoV-2; Covid 19; MIS-C

References

1. Gurdeep Singh., et al. “Comparison of Clinical Features and Outcome of Dengue Fever and Multisystem Inflammatory Syndrome in Children Associated With COVID-19 (MIS-C)”. Indian Paediatrics July 20 (2021).
2. , et al. “COVID-19 related MIS-C: A 7 case series from a tertiary care Paediatric Hospital in Qatar”. BMC Paediatrics 21 (2021): 267.
3. Iveta Raco., et al. “A 13 Case series of MIS-C during the SARS-CoV-2 pandemic in Latvia, CLIN”. PRACT 11 (2021): 363-373.
4. , et al. “Case report: A 6 case series of children with MIS-C following SARS-CoV-2 infection in Switzerland”. Frontiers in Pediatrics 8 (2021).
5. Mulstisystem inflammatory syndrome in children and adolescents with COVID-19: Scientific brief : World health organization. 15 may (2020).
6. Ahmed M., et al. “Multi system inflammatory syndrome in children : A systematic Review”. EClinical Medicine 26 (2020): 100527.
7. Mishra S., et al. “Clinical profile of dengue fever in children: A Study from southern Odisha, India”. Scientifica (Cairo) 2016 (2016): 6391594.
8. , et al. “Clinical spectrum and predictors of severity of dengue among children in 2019 outbreak : a multicenter hospital – based study in Bangladesh”. BMC Pediatrics 21 (2021): 478.

Citation

Citation: Ratan Pal Yadav., et al. “Comparison of Clinical Features, Lab Parametres and Outcome of Mis-C and Dengue Fever in Children”.Acta Scientific Medical Sciences 7.4 (2023): 78-83.

Copyright

Copyright: © 2022 Ratan Pal Yadav., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.